JPMorgan Chase & Co. Sells 27,800 Shares of LeMaitre Vascular, Inc. $LMAT

JPMorgan Chase & Co. lowered its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 18.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 121,988 shares of the medical instruments supplier’s stock after selling 27,800 shares during the quarter. JPMorgan Chase & Co.’s holdings in LeMaitre Vascular were worth $10,675,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of LMAT. Advisors Asset Management Inc. boosted its holdings in LeMaitre Vascular by 3.0% in the second quarter. Advisors Asset Management Inc. now owns 4,111 shares of the medical instruments supplier’s stock worth $341,000 after purchasing an additional 118 shares in the last quarter. Johnson Investment Counsel Inc. lifted its position in shares of LeMaitre Vascular by 0.5% in the third quarter. Johnson Investment Counsel Inc. now owns 29,792 shares of the medical instruments supplier’s stock worth $2,607,000 after buying an additional 153 shares during the last quarter. Federated Hermes Inc. boosted its stake in shares of LeMaitre Vascular by 0.4% during the 2nd quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock worth $3,294,000 after acquiring an additional 155 shares in the last quarter. Jones Financial Companies Lllp increased its holdings in shares of LeMaitre Vascular by 2.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 7,486 shares of the medical instruments supplier’s stock valued at $630,000 after acquiring an additional 158 shares during the last quarter. Finally, Illinois Municipal Retirement Fund raised its stake in shares of LeMaitre Vascular by 1.6% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 11,048 shares of the medical instruments supplier’s stock valued at $967,000 after acquiring an additional 171 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Analyst Ratings Changes

LMAT has been the subject of a number of recent analyst reports. Wells Fargo & Company upped their target price on LeMaitre Vascular from $87.00 to $94.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 26th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $95.00 price objective on shares of LeMaitre Vascular in a report on Monday, November 10th. Zacks Research lowered shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Roth Mkm reissued a “buy” rating and set a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Finally, Weiss Ratings cut shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, LeMaitre Vascular has an average rating of “Hold” and an average target price of $105.80.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director David B. Roberts sold 8,464 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $106.80, for a total transaction of $903,955.20. Following the sale, the director directly owned 17,979 shares in the company, valued at approximately $1,920,157.20. The trade was a 32.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Trent G. Kamke sold 1,044 shares of the company’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $110.29, for a total value of $115,142.76. Following the completion of the transaction, the insider owned 6,677 shares of the company’s stock, valued at $736,406.33. The trade was a 13.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 215,438 shares of company stock valued at $23,062,911 in the last quarter. Corporate insiders own 9.50% of the company’s stock.

LeMaitre Vascular Trading Down 0.2%

Shares of LMAT stock opened at $106.15 on Friday. The firm has a market capitalization of $2.42 billion, a P/E ratio of 42.29, a price-to-earnings-growth ratio of 3.06 and a beta of 0.66. LeMaitre Vascular, Inc. has a 1 year low of $71.42 and a 1 year high of $115.33. The firm’s fifty day simple moving average is $88.82 and its 200 day simple moving average is $88.73. The company has a current ratio of 12.89, a quick ratio of 10.95 and a debt-to-equity ratio of 0.43.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The company had revenue of $64.45 million for the quarter, compared to analyst estimates of $62.98 million. During the same period last year, the business posted $0.49 EPS. The business’s quarterly revenue was up 15.7% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 26th. Investors of record on Thursday, March 12th will be paid a dividend of $0.25 per share. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 annualized dividend and a yield of 0.9%. The ex-dividend date is Thursday, March 12th. LeMaitre Vascular’s dividend payout ratio is presently 31.87%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.